Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Fatty Liver | Research

Associations between life’s essential 8 and non-alcoholic fatty liver disease among US adults

Authors: Lili Wang, Jiayi Yi, Xinli Guo, Xiangpeng Ren

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is closely associated with Cardiovascular disease (CVD). We aim to examine the association of Life’s Essential 8 (LE8), the recently updated measurement of cardiovascular health (CVH), with the presence of NAFLD among US adults.

Methods

This population-based cross-sectional study used data from the National Health and Nutrition Examination Survey in 2017–2018 and included adults 20 years or older. LE8 score (range 0–100) was measured according to American Heart Association definitions and was categorized into low (0–49), moderate (50–79), and high (80–100) CVH. NAFLD was determined by transient elastography measured hepatic steatosis in the absence of other liver diseases and excess alcohol use. Multivariable logistic and restricted cubic spline models were used to assess the associations.

Results

Among 3588 participants included (weighted mean age, 48.0 years; 95% confidence interval [CI] 46.4–49.7 years), 1839 were female (weighted percentage, 51.6%; 95% CI 49.0–54.2%) and 1483 were determined to have NAFLD (weighted percentage, 36.5%; 95% CI 33.3–39.7%). The weighted mean LE8 score of the study population was 67.9 (95% CI 66.6–69.2). After the adjustment of potential confounders, higher LE8 scores were associated with reduced odds of NAFLD (odds ratio [OR] for per 10 score increase, 0.67; 95% CI 0.59–0.76) and a nonlinear dose–response relationship was observed. Similar patterns were also identified in the association of health behavior and health factor scores with NAFLD. The inversed association of LE8 score and NAFLD was significantly stronger among younger, Asian, and participants with higher education and income level.

Conclusions

LE8 and its subscales scores were negatively associated with the presence of NAFLD in non-linear fashions. Promoting adherence to optimal CVH levels may be beneficial to reduce the burden of NAFLD as well as CVD.
Appendix
Available only for authorised users
Literature
13.
go back to reference Lloyd-Jones DM, Ning H, Labarthe D, et al. Status of cardiovascular health in US adults and children using the American heart association’s new “life’s essential 8” metrics: prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018. Circulation. 2022;146(11):822–35. https://doi.org/10.1161/circulationaha.122.060911.CrossRef Lloyd-Jones DM, Ning H, Labarthe D, et al. Status of cardiovascular health in US adults and children using the American heart association’s new “life’s essential 8” metrics: prevalence estimates from the National Health and Nutrition Examination Survey (NHANES), 2013 through 2018. Circulation. 2022;146(11):822–35. https://​doi.​org/​10.​1161/​circulationaha.​122.​060911.CrossRef
Metadata
Title
Associations between life’s essential 8 and non-alcoholic fatty liver disease among US adults
Authors
Lili Wang
Jiayi Yi
Xinli Guo
Xiangpeng Ren
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Fatty Liver
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03839-0

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.